The most severe adverse reaction caused by the use of anthracyclines as chemotherapeutic agents is cardiotoxicity, which can lead to cardiac dysfunction and heart failure. Variants of the ARG, UGT1A6, and SLC28A3 genes influence the risk of suffering this adverse effect, and their analysis is becoming increasingly relevant when assessing the most suitable treatment for each patient.
Daunorubicin, Doxorubicin (Adverse Reactions)
Anthracyclines have been used for over 60 years in cancer treatment and have saved many lives. However, a significant limitation of their use is cardiotoxicity.
Daunorubicin is an anthracycline used to treat acute myeloid leukemia and acute lymphoid leukemia in children, although it can also be used in adult patients.
Doxorubicin is used to treat certain types of cancer of the urinary bladder, breast, lung, stomach, and ovary, Ewing's sarcoma, Hodgkin's lymphoma (Hodgkin's disease) and non-Hodgkin's lymphoma, Wilms' tumor, thyroid cancer, neuroblastoma, and certain leukemias.
MECHANISM OF ACTION
Anthracyclines alter DNA by interfering with topoisomerase, an enzyme essential for DNA replication and synthesis, thereby causing cell cycle arrest and programmed cell death.
CONTRAINDICATIONS
Treatment with anthracyclines is contraindicated in cases of hypersensitivity to anthracyclines and anthracenediones, persistent myelosuppression, severe infections, severe hepatic impairment, heart failure, recent myocardial infarction, severe arrhythmias, previous treatments with the same or another cardiotoxic anthracycline, pregnancy, and lactation.
SIDE EFFECTS
- Nausea, vomiting, and stomach pain
- Mouth and throat sores
- Weight loss or gain
- Muscle weakness
- Hair loss
- Tingling in the hands and feet
You should contact your doctor immediately if you develop hives, rash, itching, difficulty breathing or swallowing, or seizures.
As mentioned, cardiotoxicity is an adverse effect that limits its use and can occur acutely (during treatment), early (during the first year of treatment), or late (years or decades later). Therefore, close monitoring of patients should be carried out before, during, and after cancer therapy. The determination of LVEF (left ventricular ejection fraction) by echocardiography or with the technique of multiple-gated acquisition (MUGA) scan and magnetic resonance imaging are tests that are performed to assess for cardiotoxicity. Biochemical markers that can be used for early detection of cardiac damage are troponin T and N-terminal pro-brain natriuretic peptide (NT-proBNP).
BRAND NAMES
- Adriamycin®
- Cerubidine®
- Doxil®
- Myocet®
- Rubex®
- Vyxeos®
Genes analyzed
Bibliography
Aminkeng F, Ross CJ, Rassekh SR, et al. Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95.
Antoniadi K, Thomaidis N, Nihoyannopoulos P, et al. Prognostic Factors for Cardiotoxicity among Children with Cancer: Definition, Causes, and Diagnosis with Omics Technologies. Diagnostics (Basel). 2023 May 26;13(11):1864.
Chang VY, Wang JJ. Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity. Curr Oncol Rep. 2018 Apr 30;20(7):52.
